-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Impact of Daratumumab in the Treatment of Vulnerable Transplant Eligible Multiple Myeloma Patients and Its Utilization in Blacks

Program: Special-Interest Sessions
Session: Hematology Inclusion Pathway (HIP) Oral Presentations - Health Services Outcomes
Saturday, December 7, 2024, 6:00 PM-9:00 PM

Eden Ayele Biltibo, MD, MS

Vanderbilt University Medical Center, Nashville, TN

Disclosures: No relevant conflicts of interest to declare.